Filter

Refine by collections

Refine by date

—

Refine by access

  • Print
  • Save

Search Results

You are looking at 1 - 10 of 280 items for :

  • immunotherapy x
  • Refine by access: All content x
Clear All
Melissa Gamat University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA

Search for other papers by Melissa Gamat in
Google Scholar
PubMed Close
and
Douglas G McNeel University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA

Search for other papers by Douglas G McNeel in
Google Scholar
PubMed Close

. Immunotherapy (that involves mobilizing the immune system to attack tumor cells) has been gaining momentum as an exciting new treatment option. The first FDA-approved immunotherapy for prostate cancer, sipuleucel-T (sip-T), has highlighted the potential use of

Article Type:
Review Article
DOI:
https://doi.org/10.1530/ERC-17-0145
Volume/Issue:
Volume 24: Issue 12
Free access
Yuanliang Yan Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China

Search for other papers by Yuanliang Yan in
Google Scholar
PubMed Close
,
Qiuju Liang Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China

Search for other papers by Qiuju Liang in
Google Scholar
PubMed Close
,
Yuanhong Liu Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China

Search for other papers by Yuanhong Liu in
Google Scholar
PubMed Close
,
Shangjun Zhou Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China

Search for other papers by Shangjun Zhou in
Google Scholar
PubMed Close
, and
Zhijie Xu Department of Pathology, Xiangya Hospital, Central South University, Changsha, China

Search for other papers by Zhijie Xu in
Google Scholar
PubMed Close

side effects and may even cause late recurrence. In this scenario, cancer immunotherapies with higher efficacy and more targeted capability have positioned themselves as promising methods to win combat against BC ( Zeng et al. 2021 ). Immunotherapies

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-23-0012
Volume/Issue:
Volume 30: Issue 5
Open access
Robert C Mould Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada

Search for other papers by Robert C Mould in
Google Scholar
PubMed Close
,
Jacob P van Vloten Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada

Search for other papers by Jacob P van Vloten in
Google Scholar
PubMed Close
,
Amanda W K AuYeung Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada

Search for other papers by Amanda W K AuYeung in
Google Scholar
PubMed Close
,
Khalil Karimi Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada

Search for other papers by Khalil Karimi in
Google Scholar
PubMed Close
, and
Byram W Bridle Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada

Search for other papers by Byram W Bridle in
Google Scholar
PubMed Close

this end, cutting-edge immunotherapies show promise for providing oncologists with a novel array of therapeutic tools in the near future ( Couzin-Frankel 2013 ). However, nuances will need to be taken into consideration when applying these in the

Article Type:
Review Article
DOI:
https://doi.org/10.1530/ERC-17-0316
Volume/Issue:
Volume 24: Issue 12
Free access
Stephan Gasser Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Roche Glycart AG, Schlieren, Switzerland
Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, NUS Immunology Programme, Centre for Life Sciences, National University of Singapore, Singapore

Search for other papers by Stephan Gasser in
Google Scholar
PubMed Close
,
Lina H K Lim Department of Physiology, Yong Loo Lin School of Medicine, NUS Immunology Programme, Centre for Life Sciences, National University of Singapore, Singapore

Search for other papers by Lina H K Lim in
Google Scholar
PubMed Close
, and
Florence S G Cheung Department of Physiology, Yong Loo Lin School of Medicine, NUS Immunology Programme, Centre for Life Sciences, National University of Singapore, Singapore

Search for other papers by Florence S G Cheung in
Google Scholar
PubMed Close

Introduction Recent advances in immunotherapy have presented opportunities to eliminate cancers that were not achieved with previous standard of care therapies ( Delitto et al . 2016 ). Immune checkpoint inhibitor treatment has shown to be a

Article Type:
Review Article
DOI:
https://doi.org/10.1530/ERC-17-0146
Volume/Issue:
Volume 24: Issue 12
Free access
Andrew M K Law Tumour Development Group, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
Cancer Biology Laboratory, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia

Search for other papers by Andrew M K Law in
Google Scholar
PubMed Close
,
Elgene Lim Connie Johnson Breast Cancer Research Laboratory, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
St. Vincent’s Clinical School, Faculty of Medicine, University of New South Wales Australia, Sydney, New South Wales, Australia

Search for other papers by Elgene Lim in
Google Scholar
PubMed Close
,
Christopher J Ormandy Cancer Biology Laboratory, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
St. Vincent’s Clinical School, Faculty of Medicine, University of New South Wales Australia, Sydney, New South Wales, Australia

Search for other papers by Christopher J Ormandy in
Google Scholar
PubMed Close
, and
David Gallego-Ortega Tumour Development Group, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
St. Vincent’s Clinical School, Faculty of Medicine, University of New South Wales Australia, Sydney, New South Wales, Australia

Search for other papers by David Gallego-Ortega in
Google Scholar
PubMed Close

of immunotherapies targeting the adaptive immune system, such as checkpoint inhibitors ( Rugo et al . 2015 ). Mechanisms of immunosuppression are essential for the normal functioning of the mammary gland during development ( Clarkson et al . 2004

Article Type:
Review Article
DOI:
https://doi.org/10.1530/ERC-16-0404
Volume/Issue:
Volume 24: Issue 4
Open access
Francesca Coperchini Istituti Clinici Scientifici Maugeri IRCCS, Unit of Internal Medicine and Endocrinology, Laboratory for Endocrine Disruptors, Pavia, Italy

Search for other papers by Francesca Coperchini in
Google Scholar
PubMed Close
,
Laura Croce Istituti Clinici Scientifici Maugeri IRCCS, Unit of Internal Medicine and Endocrinology, Laboratory for Endocrine Disruptors, Pavia, Italy
PHD Course in Experimental Medicine, University of Pavia, Pavia, Italy

Search for other papers by Laura Croce in
Google Scholar
PubMed Close
,
Michele Marinò Endocrinology Unit I, Department of Clinical and Experimental Medicine, University Hospital of Pisa, University of Pisa, Pisa, Italy

Search for other papers by Michele Marinò in
Google Scholar
PubMed Close
,
Luca Chiovato Istituti Clinici Scientifici Maugeri IRCCS, Unit of Internal Medicine and Endocrinology, Laboratory for Endocrine Disruptors, Pavia, Italy
Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy

Search for other papers by Luca Chiovato in
Google Scholar
PubMed Close
, and
Mario Rotondi Istituti Clinici Scientifici Maugeri IRCCS, Unit of Internal Medicine and Endocrinology, Laboratory for Endocrine Disruptors, Pavia, Italy
Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy

Search for other papers by Mario Rotondi in
Google Scholar
PubMed Close

their role for immunotherapy. Chemokine receptors and cancer The effects of chemokines on target cells are mediated by specific receptors ( Rossi & Zlotnik 2000 , Chow & Luster 2014 ), which are responsible for the activation of a cascade of

Article Type:
Review Article
DOI:
https://doi.org/10.1530/ERC-19-0163
Volume/Issue:
Volume 26: Issue 8
Free access
Pedro Iglesias Department of Endocrinology, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain
Instituto de Investigación Sanitaria Puerta de Hierro Segovia de Arana (IDIPHISA), Majadahonda, Madrid, Spain

Search for other papers by Pedro Iglesias in
Google Scholar
PubMed Close
,
Inmaculada Peiró Clinical Nutrition Unit, Catalan Institute of Oncology, L’Hospitalet de Llobregat, Barcelona, Spain
Unit of Nutrition and Cancer-IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain

Search for other papers by Inmaculada Peiró in
Google Scholar
PubMed Close
,
Betina Biagetti Department of Endocrinology, Universitari Vall d’Hebron, Barcelona, Spain

Search for other papers by Betina Biagetti in
Google Scholar
PubMed Close
,
Miguel Paja-Fano Department of Endocrinology, Hospital Universitario de Basurto, Bilbao, Spain

Search for other papers by Miguel Paja-Fano in
Google Scholar
PubMed Close
,
Diana Ariadel Cobo Department of Endocrinology, Complejo Asistencial Universitario de León, León, Spain

Search for other papers by Diana Ariadel Cobo in
Google Scholar
PubMed Close
,
Carlos García Gómez Department of Endocrinology, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain

Search for other papers by Carlos García Gómez in
Google Scholar
PubMed Close
,
Manuel Mateu-Salat Department of Endocrinology, Hospital Sant Pau, Hospital Sant Pau, Barcelona, Spain
Department of Medicine/Endocrinology, IIB-Sant Pau, Research Center for Pituitary Diseases, Barcelona, Spain

Search for other papers by Manuel Mateu-Salat in
Google Scholar
PubMed Close
,
Idoia Genua Department of Endocrinology, Hospital Sant Pau, Hospital Sant Pau, Barcelona, Spain
Department of Medicine/Endocrinology, IIB-Sant Pau, Research Center for Pituitary Diseases, Barcelona, Spain

Search for other papers by Idoia Genua in
Google Scholar
PubMed Close
,
Margarita Majem Department of Oncology, Hospital Sant Pau, Barcelona, Spain

Search for other papers by Margarita Majem in
Google Scholar
PubMed Close
,
Mariona Riudavets Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France

Search for other papers by Mariona Riudavets in
Google Scholar
PubMed Close
,
Javier Gavira Department of Oncology, Hospital Sant Pau, Barcelona, Spain

Search for other papers by Javier Gavira in
Google Scholar
PubMed Close
,
Cristina Lamas Department of Endocrinology, Hospital General Universitario de Albacete, Albacete, Spain

Search for other papers by Cristina Lamas in
Google Scholar
PubMed Close
,
Antía Fernández Pombo Department of Endocrinology, Hospital Clínico Universitario de Santiago, Santiago de Compostela, A Coruña, Spain

Search for other papers by Antía Fernández Pombo in
Google Scholar
PubMed Close
,
Fernando Guerrero-Pérez Department of Endocrinology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain

Search for other papers by Fernando Guerrero-Pérez in
Google Scholar
PubMed Close
,
Carles Villabona Department of Endocrinology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain

Search for other papers by Carles Villabona in
Google Scholar
PubMed Close
,
José Manuel Cabezas Agrícola Department of Endocrinology, Hospital Clínico Universitario de Santiago, Santiago de Compostela, A Coruña, Spain

Search for other papers by José Manuel Cabezas Agrícola in
Google Scholar
PubMed Close
,
Susan M Webb Department of Endocrinology, Hospital Sant Pau, Hospital Sant Pau, Barcelona, Spain
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747), ISCIII, Universitat Autònoma de Barcelona, Barcelona, Spain

Search for other papers by Susan M Webb in
Google Scholar
PubMed Close
, and
Juan J Díez Department of Endocrinology, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain
Instituto de Investigación Sanitaria Puerta de Hierro Segovia de Arana (IDIPHISA), Majadahonda, Madrid, Spain
Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain

Search for other papers by Juan J Díez in
Google Scholar
PubMed Close

Introduction Checkpoint inhibitor immunotherapy has been shown to be an effective therapy in a wide variety of malignant tumors, such as advanced melanoma, renal carcinoma, non-small cell lung cancer, head and neck cancer, urothelial carcinoma

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-21-0228
Volume/Issue:
Volume 28: Issue 12
Restricted access
Mirela Diana Ilie Inserm U1052, CNRS UMR5286, Claude Bernard Lyon 1 University, Cancer Research Center of Lyon, Lyon, France
Endocrinology Department, ‘C.I. Parhon’ National Institute of Endocrinology, Bucharest, Romania

Search for other papers by Mirela Diana Ilie in
Google Scholar
PubMed Close
,
Alexandre Vasiljevic Inserm U1052, CNRS UMR5286, Claude Bernard Lyon 1 University, Cancer Research Center of Lyon, Lyon, France
Pathology Department, Reference Center for Rare Pituitary Diseases HYPO, ‘Groupement Hospitalier Est’ Hospices Civils de Lyon, Bron, France

Search for other papers by Alexandre Vasiljevic in
Google Scholar
PubMed Close
,
Emmanuel Jouanneau Inserm U1052, CNRS UMR5286, Claude Bernard Lyon 1 University, Cancer Research Center of Lyon, Lyon, France
Neurosurgery Department, Reference Center for Rare Pituitary Diseases HYPO, ‘Groupement Hospitalier Est’ Hospices Civils de Lyon, Bron, France

Search for other papers by Emmanuel Jouanneau in
Google Scholar
PubMed Close
, and
Gérald Raverot Inserm U1052, CNRS UMR5286, Claude Bernard Lyon 1 University, Cancer Research Center of Lyon, Lyon, France
Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, ‘Groupement Hospitalier Est’ Hospices Civils de Lyon, Bron, France

Search for other papers by Gérald Raverot in
Google Scholar
PubMed Close

). Here, we present an overview of immunotherapy in pituitary carcinomas and aggressive pituitary tumors, starting with the rationale for using this therapeutic option and the implications of tumor-infiltrating lymphocytes (TILs) in anterior pituitary

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-22-0037
Volume/Issue:
Volume 29: Issue 7
Restricted access
J T W Kwon Department of Oncology, University of Oxford, Oxford, UK

Search for other papers by J T W Kwon in
Google Scholar
PubMed Close
,
R J Bryant Department of Oncology, University of Oxford, Oxford, UK
Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK

Search for other papers by R J Bryant in
Google Scholar
PubMed Close
, and
E E Parkes Department of Oncology, University of Oxford, Oxford, UK

Search for other papers by E E Parkes in
Google Scholar
PubMed Close

such resistance mechanisms creates an opportunity for the use of immunotherapies in effectively 'switching on' the immune system to recognise and eradicate cancers. There are currently two immunotherapies approved by the US Food and Drug

Article Type:
Review Article
Collections:
Top-cited articles of 2023
DOI:
https://doi.org/10.1530/ERC-21-0149
Volume/Issue:
Volume 28: Issue 8
Open access
Eva Hadadi Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium
Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium

Search for other papers by Eva Hadadi in
Google Scholar
PubMed Close
and
Hervé Acloque INSERM U935, University Paris Saclay, Villejuif, Ile-de-France, France
Université Paris-Saclay, INRAE, AgroParisTech, GABI, Jouy-en-Josas, Ile-de-France, France

Search for other papers by Hervé Acloque in
Google Scholar
PubMed Close

loop maintaining immunosuppression. Finally, it also affects the efficiency of therapy because it is now clear that specific E/M states in cancer cells exhibit different levels of chemo and immunotherapy resistance ( Fig. 4 ). To tone down this dynamic

Article Type:
Review Article
DOI:
https://doi.org/10.1530/ERC-20-0390
Volume/Issue:
Volume 28: Issue 2
Free access